Share
8,897 Posts.
lightbulb Created with Sketch. 1468
clock Created with Sketch. 04/02/25
09:04
Share
Originally posted by truss20:
↑
One has FDA approval for paediatric SR-aGvHD, which is estimated to be approximately 15% of the adult SR-aGvHD market. Then, said company (for clarity, Mesoblast), wants a label extension to a third-line treatment for adult SR-aGvHD. Cynata, on the other hand, are targeting High-Risk aGvHD. The difference in market size between what Mesoblast and Cynata are targeting is stark.
Expand
"To contextualise this, you need to understand that:"
(20min delay)